FDA Schedules Advisory Panel on Capricor's DMD Cell Therapy BLA
Regulatory Inflection
Company Background
Capricor Therapeutics is a San Diego-based clinical-stage biotechnology company whose entire commercial fate rests on a single asset: Deramiocel, an allogeneic, cardiosphere-derived cell therapy for cardiomyopathy associated with Duchenne muscular dystrophy. DMD is a fatal genetic disease affecting approximately 15,000 people in the United States, primarily boys, with no approved therapy targeting its cardiac manifestations. Cardiomyopathy is the leading cause of death in DMD patients.
Capricor has generated no product revenue since the end of 2024, when it exhausted the recognition of $50 million in milestone payments from its U.S. distribution partner, Nippon Shinyaku. The company lost approximately $105 million in 2025 and $33.9 million in the first quarter of 2026 alone. A December 2025 public offering raised approximately $162 million in net proceeds, leaving the company with roughly $279 million in cash as of March 31, 2026, which management says will support operations into the fourth quarter of 2027.
The company is simultaneously managing a high-stakes regulatory process and active litigation. On May 7, 2026, Capricor filed suit against Nippon Shinyaku and its U.S. subsidiary, NS Pharma, seeking to rescind its U.S. distribution agreement and obtain a preliminary injunction. The complaint alleges a fundamental pricing flaw — tied to the interaction between the contract's pricing formula and Medicare Part B reimbursement rules — that would render distribution of Deramiocel commercially unviable. According to the complaint, once Medicare's average sales price calculation takes effect after the first two quarters of sales, the reimbursement ceiling would make it economically irrational for any party in the supply chain to sell or administer the therapy. Capricor states in the complaint that it accepted NS Pharma's repudiation of the agreement on May 6, 2026.
What Was Disclosed
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee has scheduled a meeting for July 29, 2026, to discuss Capricor's Biologics License Application seeking approval of Deramiocel for Duchenne muscular dystrophy. The PDUFA target action date remains August 22, 2026. The advisory committee meeting will be available for live streaming.
The BLA is supported by the Phase 3 HOPE-3 trial, a 106-patient, randomized, double-blind, placebo-controlled study that met its primary endpoint — Performance of Upper Limb (PUL v2.0), a measure of arm and hand function — with statistical significance (p=0.03), and the key secondary cardiac endpoint of left ventricular ejection fraction (LVEF, p=0.04). All other Type I error-controlled secondary endpoints also achieved statistical significance. Additional analyses presented at conferences in early 2026 showed a significant reduction in myocardial fibrosis by late gadolinium enhancement versus placebo and approximately 83% slowing of disease progression on a daily-living task measure versus placebo (p=0.018). Management states the BLA is "on track" for the August PDUFA date.
Capricor's CEO Linda Marbán framed the advisory committee review as an opportunity: "We are encouraged by the opportunity to bring Deramiocel before the Advisory Committee and engage directly with the FDA, the DMD patient community, and the physicians who care for them."
Why It Matters
The advisory committee call lands against a history that makes the FDA's posture worth reading carefully. The agency issued a Complete Response Letter on July 11, 2025, stating it could not approve the BLA because it did not meet the statutory requirement for substantial evidence of effectiveness and required additional clinical data. Capricor resubmitted incorporating HOPE-3 data, and the FDA resumed review on March 10, 2026, classifying it as a Class 2 resubmission with a six-month review clock. At that time, the agency stated it had not identified any potential review issues in its response to the company. The advisory committee call, which was not announced at the time of resubmission acceptance, now indicates the FDA wants independent expert input before making its decision.
Advisory committees are not inherently adverse — they can, and do, vote in favor of approval — but they are typically convened when the agency has questions it wants outside expertise to weigh in on. The HOPE-3 p-values, while crossing conventional thresholds, are at the lower end of statistical significance (0.03 and 0.04), and the original CRL identified the effectiveness standard as the central problem. The committee's vote, which is advisory and not binding, will be a significant data point heading into the August 22 PDUFA date.
Even if the FDA approves Deramiocel, Capricor faces a commercial path that is currently unresolved. The company's sole U.S. distribution agreement — with a partner it is now suing — is the subject of active litigation seeking rescission. Capricor is building its own commercial infrastructure, having recently named a Chief Commercial Officer, and management states the lawsuit does not affect the FDA review or PDUFA date. But the company would need to establish an entirely new distribution arrangement for a complex cell therapy requiring quarterly intravenous infusions, within a narrow window between any potential approval and the August PDUFA deadline. The $279 million cash position provides operational runway, but the company has no approved product, no revenue, and a distribution infrastructure that remains in legal dispute.
